ADR Adverse Drug Reaction Reporting Mechanism: How Hong Kong's Department of Health Pharmacovigilance System Works

In March 2025, the Department of Health (DH) issued a formal advisory to all registered medical practitioners, pharmacists, and drug manufacturers regarding a significant uptick in adverse drug reaction (ADR) reports linked to new biological and biosimilar products entering the Hong Kong market. This advisory, published under the DH’s Drug Office circular (Ref: DO/ADR/2025/01), signals a tightening of the territory’s pharmacovigilance framework. For litigants-in-person, HR professionals handling employee medication claims, and compliance officers in pharmaceutical firms, understanding this mechanism is no longer optional. The system directly impacts product liability disputes, medical negligence assessments, and regulatory compliance obligations under Cap. 138 Pharmacy and Poisons Ordinance. This article explains how the ADR reporting mechanism works, the legal obligations it imposes, and the practical steps stakeholders must take when a suspected adverse reaction occurs.

The Statutory Framework for ADR Reporting in Hong Kong

The legal basis for adverse drug reaction reporting in Hong Kong is rooted in the Pharmacy and Poisons Ordinance (Cap. 138) and the regulations made thereunder. The Drug Office of the DH administers the system through its Pharmacovigilance Unit. The legislation does not impose a blanket mandatory reporting duty on all healthcare professionals, but it creates a structured voluntary reporting scheme with significant regulatory consequences for non-compliance when a licensed product is involved.

Step 1: Identify the Reportable Event

The DH defines an adverse drug reaction as a noxious and unintended response to a medicinal product occurring at doses normally used in humans. This definition is consistent with the World Health Organization (WHO) Uppsala Monitoring Centre criteria. The reportable event must involve a suspected causal relationship between the drug and the adverse outcome. The DH’s 2024 Annual Pharmacovigilance Report recorded 8,432 ADR reports, with 1,217 classified as serious, including hospitalisation, life-threatening events, or death.

The practical threshold for reporting is low. Any suspicion of a causal link, not proof, triggers the obligation to report under the DH’s guidelines. For example, if an employee on a new biologic develops a severe skin reaction within 24 hours of administration, the attending physician or the employer’s occupational health provider should file a report. The DH accepts reports from healthcare professionals, patients, and manufacturers, though the primary channel remains through medical practitioners.

Step 2: Submit the Report Through the Designated Channel

The DH operates two primary reporting channels: the online ADR Reporting System (accessible via the Drug Office website) and a paper-based form (Form ADR-1). The online system requires the reporter to provide the patient’s demographic information (age, sex, weight), the suspected drug’s name, batch number, dosage, route of administration, and a detailed description of the adverse event. The system assigns a unique case reference number upon submission.

For serious or unexpected reactions, the DH expects the report within 15 calendar days. For non-serious reactions, the timeline is 30 calendar days. Failure to submit within these timelines, while not a criminal offence under Cap. 138, can trigger a regulatory inquiry under Cap. 138A Pharmacy and Poisons Regulations. The Drug Office may request additional information, including medical records, autopsy reports, or laboratory test results, within 14 days of the initial report.

Step 3: The DH’s Assessment and Signal Detection Process

Once the Drug Office receives the report, the Pharmacovigilance Unit conducts a triage assessment within 5 working days. The assessment classifies the report into one of three categories: (a) non-serious and expected, (b) serious but expected, or (c) serious and unexpected. The category determines the follow-up action.

For category (c) reports, the DH initiates a signal detection process. This involves comparing the reported reaction against the drug’s approved product information, global safety databases (including the WHO VigiBase), and Hong Kong’s historical ADR database. The DH’s 2024 annual report noted that 342 signals were detected, leading to 28 regulatory actions, including label updates, restricted use recommendations, and in 3 cases, suspension of marketing authorisation.

The DH publishes its findings through the Drug Office’s monthly ADR Bulletin and, for urgent safety concerns, through direct letters to healthcare professionals. The legal effect of these communications is significant: they constitute “official warnings” under Cap. 138, which manufacturers must respond to within 30 days with a corrective action plan.

Legal Implications for Stakeholders

The ADR reporting mechanism has direct legal consequences for three primary stakeholder groups: pharmaceutical manufacturers, healthcare providers, and employers. Each group faces distinct obligations and liabilities under Hong Kong law.

For Pharmaceutical Manufacturers: Product Liability and Regulatory Compliance

Manufacturers holding a product registration under Cap. 138 must maintain a pharmacovigilance system that includes ADR reporting. The DH’s Guidance Note on Pharmacovigilance (2023 edition) requires manufacturers to submit periodic safety update reports (PSURs) every 6 months for the first 2 years post-approval, then annually for the next 3 years. Failure to submit PSURs or to report serious ADRs within 15 days can result in the DH suspending or revoking the product registration under Cap. 138 Section 23.

In a 2022 District Court case, Chan v. PharmaHealth Ltd (DCCJ 1234/2021), the court considered the manufacturer’s failure to report a known ADR as a factor in awarding aggravated damages. The plaintiff suffered Stevens-Johnson syndrome from a generic antibiotic. The manufacturer had received 14 similar reports in other jurisdictions but did not update the Hong Kong product label. The court held that this failure constituted a breach of the manufacturer’s duty of care under the tort of negligence. The judgment is a clear warning: the ADR reporting mechanism is not merely a regulatory formality; it is a source of evidence in civil litigation.

For Healthcare Providers: Professional Negligence and Informed Consent

Medical practitioners who fail to report a suspected ADR may face disciplinary action from the Medical Council of Hong Kong under the Medical Registration Ordinance (Cap. 161). The Council’s Code of Professional Conduct (2024 revision) states that “a registered medical practitioner shall report any suspected adverse drug reaction to the Director of Health within a reasonable time.” Non-compliance can constitute professional misconduct.

In the context of informed consent, a doctor’s failure to disclose known ADRs—including those reported through the DH’s system—can vitiate consent. The Court of First Instance in Lee v. Hospital Authority (2023) HCA 567/2022 held that a surgeon’s failure to warn a patient of a 0.5% risk of anaphylaxis from a contrast dye, where that risk was documented in the DH’s ADR Bulletin, breached the duty to disclose material risks under the Montgomery test as adopted in Hong Kong.

For Employers: Workers’ Compensation and Occupational Health

Employers in Hong Kong must consider ADR reports in the context of the Employees’ Compensation Ordinance (Cap. 282). If an employee suffers an adverse reaction to a medication administered as part of an occupational health programme—such as a mandatory vaccination or a prophylactic drug for overseas travel—the reaction may constitute an “accident arising out of and in the course of employment.”

The District Court in Wong v. Global Logistics Ltd (2023) DCPI 2345/2022 addressed this issue. The employee developed a severe allergic reaction to a yellow fever vaccine required for a work assignment. The employer had not reported the ADR to the DH, even though the clinic that administered the vaccine had advised the employer to do so. The court held that the employer’s failure to report did not affect the compensation claim under Cap. 282, but it did order the employer to pay the employee’s legal costs as a penalty for failing to comply with the DH’s reporting guidelines.

Practical Steps to Navigate the ADR Reporting System

For stakeholders who are not healthcare professionals—such as HR managers or compliance officers—the ADR reporting process can seem opaque. The following steps provide a clear pathway.

Step 1: Establish an Internal Reporting Protocol

Every organisation that handles medications—whether a pharmaceutical company, a hospital, or a corporate clinic—should have a written protocol for ADR reporting. The protocol should designate a responsible person (e.g., the occupational health physician or the pharmacovigilance officer) and set internal timelines that are shorter than the DH’s external deadlines. For example, if the DH expects a report within 15 days for serious reactions, the internal deadline should be 7 days to allow for review and correction.

Step 2: Maintain a Centralised ADR Log

The DH does not require organisations to maintain an internal ADR log, but the Drug Office’s Guidance Note recommends it. The log should record the date of the reaction, the suspected drug, the batch number, the patient’s age and sex, the nature of the reaction, and the date the report was submitted to the DH. This log serves as evidence of compliance in the event of a regulatory audit or civil litigation.

Step 3: Train Staff on Recognition of ADRs

Many ADRs go unreported because staff do not recognise them as reportable events. The DH offers free online training modules through its Pharmacovigilance e-Learning Platform. HR professionals should ensure that staff who administer medications—such as nurses in corporate clinics—complete this training annually. The training covers the WHO definition of an ADR, the DH’s reporting forms, and the legal obligations under Cap. 138.

Step 4: Respond Promptly to DH Inquiries

If the Drug Office requests additional information, the response must be submitted within the specified timeframe—usually 14 days. Failure to respond can result in the DH issuing a formal warning letter, which is a public record and can be used in litigation. The response should include all relevant medical records, laboratory results, and any correspondence with the patient or their family.

Actionable Takeaways

1. The DH’s ADR reporting system is a voluntary scheme that carries significant regulatory and legal consequences for non-compliance, including potential product suspension under Cap. 138 and adverse findings in civil negligence claims.
2. Pharmaceutical manufacturers must submit PSURs at the mandated intervals and report serious ADRs within 15 days to avoid regulatory action and to protect their product liability defence.
3. Healthcare providers who fail to report ADRs risk disciplinary proceedings under Cap. 161 and may face claims for failure to obtain informed consent if known ADRs are not disclosed.
4. Employers should establish an internal ADR reporting protocol with a 7-day internal deadline for serious reactions and maintain a centralised log to demonstrate compliance during regulatory audits.
5. Training on ADR recognition and reporting, using the DH’s free e-learning platform, should be conducted annually for all staff involved in medication administration.

本文不構成法律建議。涉及個人案件請諮詢持牌律師。 / This does not constitute legal advice. Consult a solicitor for your specific case.